INT57089

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.02
First Reported 1993
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 4.46
Pain Relevance 1.58

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Cel) extracellular space (Cel) extracellular region (Cel)
Golgi apparatus (Cel) protein complex (Cel) biological_process (Cel)
Anatomy Link Frequency
neutrophils 1
Cel (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cytokine 58 98.64 Very High Very High Very High
Inflammation 134 98.52 Very High Very High Very High
dexamethasone 60 93.28 High High
imagery 186 89.40 High High
Multiple sclerosis 96 88.40 High High
Pain 6 72.92 Quite High
corticosteroid 76 50.00 Quite Low
tetrodotoxin 1 25.00 Low Low
anesthesia 14 19.96 Low Low
withdrawal 6 19.56 Low Low
Disease Link Frequency Relevance Heat
Injury 84 99.66 Very High Very High Very High
INFLAMMATION 122 98.52 Very High Very High Very High
Multiple Sclerosis 120 88.40 High High
Heart Rate Under Development 28 85.40 High High
Acute-phase Reaction 2 80.88 Quite High
Adult Respiratory Distress Syndrome 100 77.76 Quite High
Herpes Zoster 6 76.60 Quite High
Alzheimer's Dementia 6 76.56 Quite High
Diarrhoea 12 74.88 Quite High
Myalgia 6 72.92 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The inhibitors of L-arginine-NO synthase L-NG-nitro arginine methyl-ester (L-NAME) and L-NOARG (L-NG-nitro arginine) reduced the NANC relaxations elicited by EFS in a dose- and time-dependent manner; L-NOARG was two times more potent than L-NAME (IC50 = 14.3 vs 25.2 microM) and these effects were partially reverted by the addition of 300-1000 microM L-arginine but not of 300-1000 microMD-arginine.
Negative_regulation (inhibitors) of arginine methyl-ester
1) Confidence 0.02 Published 1993 Journal Braz. J. Med. Biol. Res. Section Abstract Doc Link 8136734 Disease Relevance 0 Pain Relevance 0
Indeed, applying multivariate analysis we observed a trend towards a significant reduction in CEL number and volume over time in the group with IFN-?
Negative_regulation (reduction) of CEL
2) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2276246 Disease Relevance 0.28 Pain Relevance 0.19
Atorvastatin treatment led to a substantial reduction in the number and volume of CEL in two-sided multivariate analysis (p?
Negative_regulation (reduction) of CEL
3) Confidence 0.02 Published 2008 Journal PLoS ONE Section Abstract Doc Link PMC2276246 Disease Relevance 0.36 Pain Relevance 0.31
Regarding primary endpoints, our data are comparable to this study as we observed (i) a decrease in mean CEL number from 2 to 1.52 (as compared to a decrease from 2.31 to 1.30 reported by Vollmer et al. [6]), and (ii) a reduction of CEL volume from 120 mm3 to 106 mm3 (as compared to a decrease from 234 mm3 to 139 mm3 reported by Vollmer et al.).
Negative_regulation (decrease) of CEL
4) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2276246 Disease Relevance 0.38 Pain Relevance 0.10
Treatment with high-dose atorvastatin resulted in a significant reduction of CEL number compared to baseline in the multivariate analysis (p?
Negative_regulation (reduction) of CEL
5) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2276246 Disease Relevance 0.06 Pain Relevance 0.04
Moreover, we observed a pronounced reduction in number and volume of CEL under treatment when compared to baseline.
Negative_regulation (reduction) of CEL
6) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2276246 Disease Relevance 0.58 Pain Relevance 0.12
Regarding primary endpoints, our data are comparable to this study as we observed (i) a decrease in mean CEL number from 2 to 1.52 (as compared to a decrease from 2.31 to 1.30 reported by Vollmer et al. [6]), and (ii) a reduction of CEL volume from 120 mm3 to 106 mm3 (as compared to a decrease from 234 mm3 to 139 mm3 reported by Vollmer et al.).
Negative_regulation (reduction) of CEL
7) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2276246 Disease Relevance 0.30 Pain Relevance 0.09
BAL protein levels were reduced with HTS, although these differences were not statistically significant [Table 2].
Negative_regulation (reduced) of BAL protein
8) Confidence 0.01 Published 2008 Journal BMC Pulm Med Section Body Doc Link PMC2467400 Disease Relevance 0.44 Pain Relevance 0.07
BAL IL-6 [Figure 2], and BAL protein levels [Table 1] were reduced with HTS, although these differences were not statistically significant [Figure 3].
Negative_regulation (reduced) of BAL protein
9) Confidence 0.01 Published 2008 Journal BMC Pulm Med Section Body Doc Link PMC2467400 Disease Relevance 0.33 Pain Relevance 0.05
Antenatal betamethasone decreased protein in BAL, but had no effect on the number of inflammatory cells recovered by BAL.
Negative_regulation (decreased) of BAL associated with inflammation
10) Confidence 0.01 Published 2009 Journal Respir Res Section Body Doc Link PMC2802354 Disease Relevance 0.83 Pain Relevance 0.29
Antenatal treatment with betamethasone decreased the injury score, protein leak, and pro-inflammatory cytokines compared to animals receiving no treatment (Injury), and tended to decrease neutrophils in the BAL.
Negative_regulation (decrease) of BAL in neutrophils associated with inflammation, injury and cytokine
11) Confidence 0.01 Published 2009 Journal Respir Res Section Body Doc Link PMC2802354 Disease Relevance 0.90 Pain Relevance 0.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox